In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides

Zmira Samra*, Shoshana Rosenberg, Yigal Soffer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We tested the in vitro activity of levofloxacin, ciprofloxacin, doxycycline, tetracycline, erythromycin, roxithromycin, clarithromycin and azithromycin against 110 clinical isolates of Mycoplasma hominis. The minimal inhibitory concentrations (MICs) were determined with the Etest. The minimal concentrations at which 90% of the isolates were inhibited (MIC90) were 0.064 μg/ml doxycycline and 0.19 μg/ml tetracycline. In 9 isolates (8.1%), the MIC for doxycycline was 4-12 μg/ml. These isolates were also resistant to tetracycline with a MIC of 32-128 μg/ml. No significant difference was found between doxycycline and tetracycline (p = 0.076). Comparison of the two quinolones revealed that the MIC90 for levofloxacin was 0.19 μg/ml and for ciprofloxacin, 0.5 μg/ml. A significant difference was found between doxycycline/tetracycline and levofloxacin or ciprofloxacin (p = 0.0001), and between levofloxacin and ciprofloxacin (p = 0.001). All the isolates were highly resistant to the macrolides with MIC ≥ 256 μg/ml. This finding has important implications for cases in which Mycoplasma infection is suspected and culture and/or in vitro susceptibility tests are not available.

Original languageEnglish
Pages (from-to)359-361
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Volume44
Issue number4
DOIs
StatePublished - 1 Dec 2002
Externally publishedYes

Fingerprint

Dive into the research topics of 'In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides'. Together they form a unique fingerprint.

Cite this